0001209191-16-150176.txt : 20161115 0001209191-16-150176.hdr.sgml : 20161115 20161115162221 ACCESSION NUMBER: 0001209191-16-150176 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161110 FILED AS OF DATE: 20161115 DATE AS OF CHANGE: 20161115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222711928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PEHL MICHAEL F. CENTRAL INDEX KEY: 0001677939 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34912 FILM NUMBER: 161999962 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-11-10 0 0000816284 CELGENE CORP /DE/ CELG 0001677939 PEHL MICHAEL F. C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 0 1 0 0 See remarks Common Stock 2016-11-10 4 M 0 938 36.36 A 2566 D Common Stock 2016-11-10 4 M 0 781 114.08 A 3347 D Common Stock 2016-11-10 4 M 0 1668 34.70 A 5015 D Common Stock 2016-11-10 4 M 0 1668 36.68 A 6683 D Common Stock 2016-11-10 4 M 0 1668 49.48 A 8351 D Common Stock 2016-11-10 4 M 0 1876 59.24 A 10227 D Common Stock 2016-11-10 4 M 0 1876 71.33 A 12103 D Common Stock 2016-11-10 4 M 0 1876 78.12 A 13979 D Common Stock 2016-11-10 4 M 0 1874 74.30 A 15853 D Common Stock 2016-11-10 4 M 0 1250 87.64 A 17103 D Common Stock 2016-11-10 4 M 0 625 103.10 A 17728 D Common Stock 2016-11-10 4 M 0 1250 117.18 A 18978 D Common Stock 2016-11-10 4 M 0 625 118.57 A 19603 D Common Stock 2016-11-10 4 M 0 781 109.90 A 20384 D Common Stock 2016-11-10 4 M 0 1668 36.47 A 22052 D Common Stock 2016-11-10 4 S 0 20424 121.03 D 1628 D Common Stock 2016-11-10 4 S 0 1628 121.15 D 0 D Stock Option (right to buy) 36.36 2016-11-10 4 M 0 938 0.00 D 2022-01-30 Common Stock 938 0 D Stock Option (right to buy) 114.08 2016-11-10 4 M 0 781 0.00 D 2025-11-09 Common Stock 781 2344 D Stock Option (right to buy) 34.70 2016-11-10 4 M 0 1668 0.00 D 2022-07-30 Common Stock 1668 0 D Stock Option (right to buy) 36.68 2016-11-10 4 M 0 1668 0.00 D 2022-10-31 Common Stock 1668 0 D Stock Option (right to buy) 49.48 2016-11-10 4 M 0 1668 0.00 D 2023-01-28 Common Stock 1668 1668 D Stock Option (right to buy) 59.24 2016-11-10 4 M 0 1876 0.00 D 2023-04-29 Common Stock 1876 1876 D Stock Option (right to buy) 71.33 2016-11-10 4 M 0 1876 0.00 D 2023-07-29 Common Stock 1876 1876 D Stock Option (right to buy) 78.12 2016-11-10 4 M 0 1876 0.00 D 2023-10-28 Common Stock 1876 1876 D Stock Option (right to buy) 74.30 2016-11-10 4 M 0 1874 0.00 D 2024-02-03 Common Stock 1874 3752 D Stock Option (right to buy) 87.64 2016-11-10 4 M 0 1250 0.00 D 2024-07-28 Common Stock 1250 2500 D Stock Option (right to buy) 103.10 2016-11-10 4 M 0 625 0.00 D 2024-10-27 Common Stock 625 1250 D Stock Option (right to buy) 117.18 2016-11-10 4 M 0 1250 0.00 D 2024-12-19 Common Stock 1250 3750 D Stock Option (right to buy) 118.57 2016-11-10 4 M 0 625 0.00 D 2025-02-02 Common Stock 625 1875 D Stock Option (right to buy) 109.90 2016-11-10 4 M 0 781 0.00 D 2025-05-04 Common Stock 781 2344 D Stock Option (right to buy) 36.47 2016-11-10 4 M 0 1668 0.00 D 2022-04-30 Common Stock 1668 0 D The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $120.99 to $121.22, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). The option was fully exercisable. The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated on April 15, 2015). President Hematology & Oncology /s/ Peter N. Kellogg ________________________________________________________________ Peter N. Kellogg, Attorney-in-Fact 2016-11-14